What Changed in the 2026 Hormone Therapy Label Update

Key Takeaways

• In February 2026, FDA approved clearer labels for a first batch of six menopausal hormone therapy products.
• On those labels, the statements about cardiovascular disease, breast cancer and probable dementia came out of the boxed warning, the box at the start of the label for its most serious risks.
• For vaginal estrogen, FDA asked manufacturers to take every statement out of the boxed warning.
• Labels are being updated one product at a time, so check the leaflet that comes with yours.

Many women aren't sure what hormone therapy involves. In an AARP survey, women in perimenopause who hadn't used hormone therapy said they had never heard of it (18%) or didn't know enough about it (26%).

Yet hormone therapy remains the most effective treatment for hot flashes and night sweats, and for the vaginal, vulvar and urinary symptoms of menopause. That's the view of The Menopause Society's 2022 position statement. The 2026 update gives you and your provider a clearer label to start from.

The Four Types of Hormone Therapy

FDA groups hormone therapy into four main types:

• Estrogen and progestogen together: for women with a uterus, most often as pills or skin patches.
• Estrogen alone, whole-body: pills, skin patches, a spray, a gel or a vaginal ring, usually for women who have had their uterus removed.
• Progestogen alone: pills added to whole-body estrogen in women with a uterus, to protect against cancer of the uterus.
• Vaginal estrogen: a cream, tablet, insert or ring applied to the vaginal area to treat vaginal symptoms.

Your provider can help you decide which type fits your symptoms, health history and preferences.

What FDA Changed on Hormone Therapy Labels

On February 12, 2026, FDA approved labeling changes to six menopausal hormone therapy products. The statements about cardiovascular disease, breast cancer and probable dementia came out of the boxed warning, the box of safety statements at the top of a prescription label.

The agency started the change in November 2025 after reviewing the scientific literature. In that request, it also asked manufacturers to:

• Drop the "lowest effective dose for the shortest amount of time" line from the boxed warning.
• Remove the probable dementia warning from the labeling altogether.
• Add a new consideration to whole-body (systemic) products: starting therapy for moderate to severe hot flashes and night sweats in women under 60, or within 10 years of menopause.

The Six Updated Products

FDA's list, updated February 12, 2026, names six products. They cover all four types of hormone therapy:

• Progestogen alone, for women with a uterus who use whole-body estrogen: Prometrium
• Systemic estrogen alone: Divigel, Cenestin, Enjuvia
• Topical vaginal estrogen: Estring
• Systemic estrogen and progestogen: Bijuva

Start with an evaluation

The One Boxed-Warning Statement That Stays

For estrogen used alone in a form that works throughout the body, only one boxed-warning statement stays, and it's about the lining of the uterus. It applies if you have a uterus. It's also why a progestogen such as progesterone, which helps protect the uterine lining, is often prescribed alongside estrogen.

For vaginal estrogen, FDA's request goes further. It asks for every boxed statement to come out, and for the label's safety information to be shortened to focus on local use.

What the Label Update Means for You

It means you and your provider can start from a clearer description of hormone therapy than the one on labels in 2025. The change comes from FDA's review of existing research, and your provider still looks at how it applies to your own health history, symptoms and goals.

Updates arrive product by product, so your own leaflet may still show the older wording.

Staying Safe on Hormone Therapy

Your provider is part of every step:

• Before you start: your provider reviews your health history, symptoms and lab results.
• As you go: your provider checks in on how you're doing and adjusts your plan if needed.
• Side effects you might notice: those listed on an estradiol label include breast tenderness, nausea and spotting.
• If you have a uterus: your provider will talk with you about whether you need progesterone with your estrogen.

Tell your provider about any new vaginal bleeding or changes in your breasts, and ask before you change your dose or how often you take it.

Questions to Ask About Hormone Therapy

Some questions to start with:

• Which type of hormone therapy fits my symptoms?
• What do the label changes mean for me?
• Do I need progesterone too?

If you're weighing whether hormone therapy suits you, start with an evaluation. A licensed provider will go through your history with you and help you choose what comes next. The estradiol cream guide covers how a vaginal cream fits in.

Frequently Asked Questions